Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.30 USD
-0.02 (-1.52%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Marinus Pharmaceuticals, Inc. [MRNS]
Reports for Purchase
Showing records 1 - 20 ( 59 total )
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
RAISE Misses One Co-Primary Endpoint, Though We See Strong Efficacy Signal and Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ztalmy Continues to Prove Its Value as We Await Full RAISE Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Down But Not Out; Not Hard For Us to See Path Forward in RSE Though Lower Visibility Leads Us to Lower PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Initial Thoughts After Ganaxolone Misses at Interim Analysis; Path Forward Exists But Less Straightforward
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Call With Marinus Management Reinforces Our Confidence as RAISE Readout Fast Approaches; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
All Rise: Our Comprehensive Preview of the RAISE Readout, A Comprehensive Slide Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pivotal Year for Marinus with Key Readouts as RAISE Looms on the Horizon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Pivotal Year Gets Off to a Strong Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Additional Takeaways Following AES; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
AES Shows Strong Interest in Ganaxolone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for MRNS 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Next Generation Ganaxolone Achieves Key Goals; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
5 Takeaways From the Marinus Analyst Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ztalmy Keeps Shining While RSE Analysis Sees Modest Delay; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways from our Conversation with Marinus Pharmaceuticals Management; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Focus Turns to RAISE Though Ztalmy Continues to Make Gains; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ztalmy to Ztay on an Upward Trajectory During 2023, All Eyes Turn to RAISE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D